Plasma Fractionation Market Set to Reach $12.7 Billion by 2035, Driven by Growing Demand for Plasma-Derived Therapies and Advancements in Fractionation Manufacturing Technologies.

The plasma fractionation market is projected to grow from $4.8 billion in 2024 to $12.7 billion by 2035, with a CAGR of 9.2%. The market is driven by the increasing demand for plasma-derived therapies for various disease indications, such as oncological disorders, hematological disorders, and immunological disorders. Key players in the market include Baxter, CSL, Grifols, and Takeda. The market is expected to be hindered by challenges such as limited blood plasma supply and a lack of proper regulatory framework.

The plasma fractionation market is projected to grow from $4.8 billion in 2024 to $12.7 billion by 2035, with a compound annual growth rate (CAGR) of 9.2% [1]. This significant growth is driven by the increasing demand for plasma-derived therapies used to treat various disease indications, including oncological disorders, hematological disorders, and immunological disorders. The market is expected to be hindered by challenges such as limited blood plasma supply and a lack of proper regulatory framework.

Market Drivers and Challenges

The plasma fractionation market is primarily driven by the growing demand for plasma-derived therapies. These therapies are crucial for treating several disease indications, such as oncological disorders, hematological disorders, pulmonary disorders, and immunological disorders. Plasma fractionation is a critical step in ensuring the separation and purification of key blood plasma components, such as immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These refined blood plasma components are then used for the formulation of therapeutics.

Among all plasma-derived therapies, demand for immunoglobulins is anticipated to be the highest. Despite challenges such as limited blood plasma supply and a lack of proper regulatory framework, the popularity of plasma-derived therapies is rapidly increasing due to a broader spectrum of target disease indications, improved diagnosis rates, and higher standards of healthcare in emerging markets.

Key Insights and Market Segments

The market is segmented based on various parameters, including the type of company, scale of operation, type of plasma-derived therapeutic products manufactured, therapeutic areas of plasma-derived products, and key geographical regions. In-house manufacturers currently occupy the largest share of the plasma fractionation market, followed by contract service providers. The commercial scale holds the highest share of the market based on the scale of operation. Immunoglobulins hold the maximum share of the market based on the type of plasma-derived therapeutic products manufactured.

Key Players

Key players in the plasma fractionation market include Baxter, CSL, Grifols, and Takeda. These companies are well-established players with capabilities for offering formulation services and expanding their existing capabilities across various regions. For instance, players based in Europe have been actively involved in mergers and acquisitions, while those in North America have been expanding their facilities.

Future Outlook

In the long term, the plasma-derived therapies for immunological disorders are likely to emerge as key growth drivers of the plasma fractionation market. Asia-Pacific is anticipated to be the fastest-growing region, with a higher CAGR compared to other regions. The market is expected to witness an annualized growth of ~10% over the next decade.

References

[1] https://www.globenewswire.com/news-release/2025/09/03/3143487/28124/en/Plasma-Fractionation-Market-Industry-Report-2025-2035-Market-Trends-Key-Players-and-Global-Capacity-Outlook.html